Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: A placebo-controlled study in rats

Thrombosis Research

Volumn 130, Issue 1, 2012, Pages 65-69

  Grzesk, Grzegorz ^a   Kozinski, Marek ^a   Navarese, Eliano Pio ^a,b   Krzyzanowski, Marek ^a   Grzesk, Elzbieta ^a   Kubica, Aldona ^a   Siller Matula, Jolanta Maria ^c   Castriota, Fausto ^b   Kubica, Jacek ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b GVM Care Research   (Italy)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

clopidogrel; off target effect; platelets; prasugrel; ticagrelor; vascular smooth muscle cells

Indexed keywords

ADENOSINE DIPHOSPHATE; ARGININE; CLOPIDOGREL; PHENYLEPHRINE; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; MUSCLE FIBER CONTRACTION; NONHUMAN; PERFUSION; PRIORITY JOURNAL; RAT; REDUCTION; VASCULAR SMOOTH MUSCLE;

ADENOSINE; ADENOSINE DIPHOSPHATE; ANIMALS; ARTERIES; MUSCLE CONTRACTION; MYOCYTES, SMOOTH MUSCLE; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RATS; RATS, WISTAR; THIOPHENES; TICLOPIDINE;

EID: 84861830383     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.12.029     Document Type: Article

References (32)

1. C. Baigent, L. Blackwell, R. Collins, J. Emberson, J. Godwin, and R. Peto Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
2. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
3. E.P. Navarese, M. Verdoia, A. Schaffer, P. Suriano, M. Kozinski, and F. Castriota Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials QJM 104 2011 561 569
4. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
5. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, and C. Held Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
6. J.T. Brandt, C.D. Payne, S.D. Wiviott, G. Weerakkody, N.A. Farid, and D.S. Small A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 2007 66.e9 66.e16
7. P.A. Gurbel, K.P. Bliden, K. Butler, U.S. Tantry, T. Gesheff, and C. Wei Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
8. V.L. Serebruany Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor Cardiology 117 2010 231 233
9. V.L. Serebruany The TRITON versus PLATO trials: differences beyond platelet inhibition Thromb Haemost 103 2010 259 261
10. V.L. Serebruany, and D. Atar The PLATO trial: do you believe in magic? Eur Heart J 31 2010 764 767
11. A.K. Wihlborg, L. Wang, O.O. Braun, A. Eyjolfsson, R. Gustafsson, and T. Gudbjartsson ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels Arterioscler Thromb Vasc Biol 24 2004 1810 1815
12. C. Högberg, H. Svensson, R. Gustafsson, A. Eyjolfsson, and D. Erlinge The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature Int J Cardiol 142 2010 187 192
13. C. Gachet P2 receptors, platelet function and pharmacological implications Thromb Haemost 99 2008 466 472
14. N. von Beckerath, D. Taubert, G. Pogatsa-Murray, A. Wieczorek, E. Schömig, and A. Schömig A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite Thromb Haemost 93 2005 789 791
15. A. Sugidachi, T. Ogawa, A. Kurihara, K. Hagihara, J.A. Jakubowski, and M. Hashimoto The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite J Thromb Haemost 5 2007 1545 1551
16. G. Froldi, R. Bertin, P. Dorigo, M. Montopoli, and L. Caparrotta Endothelium-independent vasorelaxation by ticlopidine and clopidogrel in rat caudal artery J Pharm Pharmacol 63 2011 1056 1062
17. P. André, F. DeGuzman, H. Haberstock-Debic, S. Mills, Y. Pak, and M. Inagaki Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding J Pharmacol Exp Ther 338 2011 22 30
18. S.B. Bender, Z.C. Berwick, M.H. Laughlin, and J.D. Tune Functional contribution of P2Y1 receptors to the control of coronary blood flow J Appl Physiol 111 2011 1744 1750
19. P. Winter, and K.A. Dora Spreading dilatation to luminal perfusion of ATP and UTP in rat isolated small mesenteric arteries J Physiol 582 2007 335 347
20. G. Patti, D. Grieco, G. Dicuonzo, V. Pasceri, A. Nusca, and G. Di Sciascio High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study J Am Coll Cardiol 57 2011 771 778
21. A. Warnholtz, M.A. Ostad, N. Velich, C. Trautmann, R. Schinzel, and U. Walter A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study Atherosclerosis 196 2008 689 695
22. C.N. Hess, R. Kou, R.P. Johnson, G.K. Li, and T. Michel ADP signaling in vascular endothelial cells: ADP-dependent activation of the endothelial isoform of nitric-oxide synthase requires the expression but not the kinase activity of AMP-activated protein kinase J Biol Chem 284 2009 32209 32224
23. F.R. Giachini, D.A. Osmond, S. Zhang, F.S. Carneiro, V.V. Lima, and E.W. Inscho Clopidogrel, independent of vascular P2Y12 receptor, improves the arterial function in small mesenteric arteries from Ang II-hypertensive rats Clin Sci 118 2010 463 471
24. A. Jakubowski, S. Chlopicki, R. Olszanecki, J. Jawien, M. Lomnicka, and J.P. Dupin Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart Prostaglandins Leukot Essent Fatty Acids 72 2005 139 145
25. T. Heitzer, V. Rudolph, E. Schwedhelm, M. Karstens, K. Sydow, and M. Ortak Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects Arterioscler Thromb Vasc Biol 26 2006 1648 1652
26. K. Wang, X. Zhou, Y. Huang, M. Khalil, D. Wiktor, and J.J. van Giezen Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model Thromb Haemost 104 2010 609 617
27. T. Waehre, J.K. Damås, T.M. Pedersen, L. Gullestad, A. Yndestad, and A.K. Andreassen Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study J Thromb Haemost 4 2006 2140 2147
28. L. Molero, A. López-Farré, P.J. Mateos-Cáceres, R. Fernández-Sánchez, M. Luisa Maestro, and J. Silva Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery Br J Pharmacol 146 2005 419 424
29. D.P. Vivekananthan, D.L. Bhatt, D.P. Chew, F.J. Zidar, A.W. Chan, and D.J. Moliterno Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention Am J Cardiol 94 2004 358 360
30. S. Husted, R.F. Storey, R.A. Harrington, H. Emanuelsson, and C.P. Cannon Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel Clin Cardiol 33 2010 206 212
31. J.J. van Giezen, J. Sidaway, P. Glaves, I. Kirk, and J.A. Björkman Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model J Cardiovasc Pharmacol Ther Jun 22 2011 [Epub ahead of print]
32. V.L. Serebruany Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial? Am Heart J 161 2011 1 4